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Morphologic and/or metabolic imaging re-assessment was 
performed between 12 and 26 weeks after treatment. 
Disease-free survival (DFS) was calculated from the end of 
treatment to the date of first event of disease recurrence. 
Overall survival (OS) was calculated from the end of 
treatment to the date of death from any cause or of last 
follow-up. 
 
Results: All patients are evaluable for acute toxicity 
assessment while clinical outcome has been analyzed in 
29/37 (79,4%) patients, with a median follow-up of 8 months 
(range 3-69). Baseline clinical features of the whole cohort 
are summarized in table 1. Concurrent CT was given in 30 
patients (81.1%) and in 23 of them (76.6%) the preferred 
regimen consisted of 5 – fluoruracil – mitomycin C 
combination. A sequential IMRT schedule was delivered in 9 
patients (24.3%) while 28 (75.7%) underwent IMRT-SIB. In 22 
patients (60%) treatment was completed without any 
interruptions while the median duration of treatment breaks 
was 7 days (range 1-16) in the remaining group. In terms of 
acute toxicity, the rate of G3+ diarrhea and dermatitis was 
8.1% and 13.5%, respectively. No G3+ GU and hematological 
toxicities were reported. Complete response was achieved in 
21/29 patients (72.4%), partial response/stable disease in 7 
(24.1%) and local disease progression in 1 (3%). All patients 
were alive at last follow-up. The 1-year OS, DFS, and 
colostomy-free survival were 100%, 85%and 96%, respectively.  
 
 
 
 
Conclusion: In our dual institution experience, concurrent 
chemo-radiation with TO for SCAC was associated with a 
favorable acute toxicity profile, in line with published 
experiences. Considering the prevalence of very advanced 
loco-regional disease in our cohort, early response 
assessment is noteworthy, although a longer follow-up is 
needed to confirm the long-term benefit and to evaluate the 
incidence of late toxicity.  
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Purpose or Objective: To report the clinical results of six 
years experience with Adaptive Radiotherapy concomitant 
with chemotherapy in the preoperative treatment of rectal 
cancer. 
 
Material and Methods: Patients (pts) with T3/T4N0 or any 
TN+ rectal adenocarcinoma were enrolled in an observational 
trial. Chemotherapy consisted of Oxaliplatin 100mg/m2 on 
the days -14, 0, +14, and continuous infusion 5-FU 
200mg/m2/day from day -14 to the end of radiotherapy. 
Concomitant Radiotherapy (RT) started on the day 0, was 
delivered with Tomotherapy, and consisted of 41.4 Gy in 18 
fractions (frs) (2.3 Gy/fr) to the PTV defined as CTV, the 
tumor and regional lymph-nodes contoured on the initial 
simulation CT and MRI, with a margin of 0.5 cm. Simulation 
CT and MRI were repeated after two cycles of chemotherapy 
and 9 frs of RT for the planning of the adaptive RT phase: 
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PTVadapt was generated by adding a margin of 5 mm to the 
residual tumour visible on the intermediate MRI images 
(GTVadapt). A simultaneous integrated boost of 3.0 Gy/fr 
was delivered to PTVadapt on the last 6 frs of RT until a total 
dose of 45.6 Gy in 18 frs. 
 
Results: From September 2009 to September 2015, 56 pts 
completed the preoperative treatment. Toxicity. No G4 
toxicity occurred. G3 toxicity was only gastrointestinal: 
diarrhoea in 9/56 pts (16%), and proctitis in 3/56 (5%). 
Diarrhoea started before the adaptive RT phase in all the 
cases. Treatment feasibility. Two pts interrupted 
radiotherapy after 7 and 13 fractions, respectively, the 
remaining pts (54/56=96%) completed the treatment; the 
median duration of RT was 25 days (22-36 days). 47/56 pts 
(84%) and 45/56 pts (80%) received the full dose of 
oxaliplatin and 5-FU, respectively: 18% of pts received 
moderately reduced doses (60%-90%), and only two pts (2%) 
received less than 60% of the planned dose. Responses. Two 
pts achieved clinical complete response (cCR) and refused 
surgery, 1 pt was lost, 1 pt had early distant progression. 
Fifty-two pts underwent surgery (49 R0, 3 R1). Fifteen pts 
(29%) had pathological complete response (pCR); 24/52 (46%) 
had Tumor Regression Grade 3 response: 14/52 (27%) and 
6/52 (12%) had ≤5%, and 6 -10% residual viable cells, 
respectively. Regarding the two patients with cCR who 
refused surgery, 1 pt is still in cCR after 69 months, 1 pt had 
local relapse and underwent transanal resection 1 year after 
the preoperative treatment. 
 
Conclusion: This study confirms that adaptive Radiotherapy 
with Tomotherapy concomitant with oxaliplatin based 
chemotherapy in the preoperative treatment of rectal cancer 
is feasible, has an acceptable G3 toxicity rate and a very 
encouraging tumour response rate. A further dose escalation 
to the PTVadapt could be feasible and could increase the pCR 
and/or cCR rates. 
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Purpose or Objective: To evaluate the contribution of 
components for intense multimodal local treatment to the 
most adverse loco-regional staging scenario of M0 rectal 
cancer. 
 
Material and Methods: From 1/00 to 12/13, 95 cT4NXM0 
patients were treated with radical intent. 54 completed 
preoperative intensified chemo-radiation (all had post-
resection intraoperative electron pelvic boost, IOERT). 
Adjuvant systemic chemotherapy was recommended 
considering individualized risk features. Incomplete and 
complete pre and intra-operative treatment cohorts were 
comparable in characteristics: male (44/55%); age >70 
(44/33%); PS 0 (46/62%); inferior segment (42/41%); grade 2 
(67/62%); cN+ (75/83%). 
 
Results: With a median follow-up time of 62 months overall, 
disease-free (DFS) and loco-regional relapse-free survival 
were superior in the cohort of complete intensification (75% 
vs 51%, p=0.009; 67% vs 54%, p=0.03; 77% vs 71%, p=0.01), 
respectively. IOERT significantly improved presacral control 
rates. Multivariate analysis indicated that uninvolved surgical 
margin and intense tumour regression grade assessed 
response, were protective for DFS. 
 
Conclusion: Multimodal preoperative approach contributed 
to remarkable cancer-control outcomes and survival in cT4M0 
rectal patients, if components of therapy are feasible to be 
maximized (including free surgical margins) and an intense 
pathological disease response is described. 
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Purpose or Objective: The utility of SCCAg as a marker for 
treatment response or relapse is unknown in anal cancer. 
 
Material and Methods: This is a retrospective analysis of 28 
patients in whom SCCAg serum level was increased prior to 
treatment (mean 6,4 ng/ml, range 1,6-19,6 ng/ml). In all 
patients, measurement of SCCAg was performed at baseline, 
after completion of chemoradiation and at each visit during 
follow-up (median 35 months, range 7-81). All patients were 
treated radically. 
 
Results: In 27 (96%) patients SCCAg level decreased to normal 
level after treatment. One remaining patient had persistent 
unreseceble tumor confirmed by pathology and persistent 
high SCCAg level. Only one of 27 patients with normalization 
of SCCAg after chemoradiation had persistent ulceration in 
the anal canal and persistent enlarger inguinal lymph node. 
This patient underwent abdominoperineal resection with 
inguinal lymphadenectomy. On pathological examination only 
a few cancer cells were found in the inguinal nodes and the 
primary tumour site was free of cancer.. In six patients, 
increase of SCCAg was observed during follow-up. In one of 
these 6 patients, locoregional recurrence was also detected 
clinically at the same time. In 4 patients, the diagnostic 
examinations performed because of elevated SCCAg reveled 
locoregional recurrence (n=2) or distant metastases (n=2). In 
one remaining patient the diagnostic examinations were 
negative; distant metastases were detected 5 months 
thereafter. The remaining 20 patients had both: sustained 
clinical complete regression and normal SCCAg level.  
 
Conclusion: This study suggests utility of SCCAg in the 
monitoring of response to chemoradiation and in the 
detection of recurrence 
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Purpose or Objective: Preoperative radiotherapy (RT), alone 
or in combination with chemotherapy (CT) is the standard of 
care in patients (pts) with locally advanced rectal cancer 
(LARC). Nevertheless in those tumors in which the down-
sizing and down-staging are necessary, (cT3 MRF - / + N0 of 
lower rectum or cT3-4 MRF + / N0-2) preoperative chemo-
radiotherapy (CT-RT) is recommended. There is a correlation 
between RT dose and response and the tumor regression 
grade (TRG) represents an independent prognostic factor. 
The aim of the study is to analyze the role of RT dose 
intensification in the preoperative treatment of LARC in 
terms of feasibility, toxicity and pathological response grade. 
 
Material and Methods: We have retrospectively analyzed 69 
pts with histological diagnosis of LARC (stage II-III) treated in 
five Italian Radiotherapy centres. The treatment programme 
included: intensity-modulated radiotherapy (IMRT) delivered 
